JoVE - Journal of Visualized Experiments
JoVE Visualize
Contact Us

Oncolytic Vaccinia Virus Encoding Aphrocallistes vastus Lectin Suppresses the Proliferation of Gastric Cancer Cells

  • 0College of Life Sciences and Medicine, Zhejiang Sci-Tech University, Hangzhou, China.
Human Gene Therapy +

|

September 25, 2024

|

September 25, 2024

View abstract on PubMed

Summary

This summary is machine-generated.

Oncolytic vaccinia virus encoding Aphrocallistes vastus lectin (oncoVV-AVL) effectively targets gastric cancer cells. This therapy enhances viral replication and induces cancer cell death and tumor necrosis.

Area Of Science

  • Oncology
  • Virology
  • Biochemistry

Background

  • Previous research demonstrated the efficacy of oncolytic vaccinia virus encoding Aphrocallistes vastus lectin (oncoVV-AVL) against colorectal and hepatocellular cancer.
  • Gastric cancer (GC) remains a significant global health challenge requiring novel therapeutic strategies.

Purpose Of The Study

  • To investigate the efficacy of oncoVV-AVL as a potential therapeutic agent for gastric cancer.
  • To elucidate the mechanisms underlying oncoVV-AVL's anti-cancer effects in GC cells.

Main Methods

  • Treatment of gastric cancer cells with oncoVV-AVL.
  • Assessment of reactive oxygen species (ROS) levels.
  • Measurement of nuclear factor erythroid 2-related factor 2 (Nrf2) expression.
  • Analysis of viral replication and cellular redox balance.
  • Evaluation of metabolic microenvironment reprogramming.
  • In vivo studies assessing tumor growth regression and necrosis.

Main Results

  • OncoVV-AVL significantly increased ROS levels and suppressed Nrf2 expression in GC cells.
  • The treatment enhanced viral replication, disrupted cellular redox balance, and led to cancer cell death.
  • OncoVV-AVL reprogrammed the metabolic microenvironment to support viral replication and cancer cell lysis.
  • In vivo, oncoVV-AVL demonstrated tumor growth regression and induced tumor tissue necrosis.

Conclusions

  • OncoVV-AVL exhibits potent anti-cancer activity against gastric cancer cells through ROS induction and redox balance disruption.
  • The virus effectively promotes its own replication within cancer cells, leading to lysis.
  • OncoVV-AVL demonstrates therapeutic potential for gastric cancer, warranting further clinical investigation.

Keywords:

Related Concept Videos

Cancer Vaccines 01:30

345

Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...

Tumor Immunotherapy 01:27

491

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

Rous Sarcoma Virus (RSV) and Cancer 01:03

5.0K

Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand  RNA genome. Its genome consists of four main open...